Drug Trial Radar · NCT03910660
A Trial of Talabostat (BXCL701) and Pembrolizumab in Participants With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
97
Actual
Start
Jun 10, 2019
Primary completion
Oct 31, 2023
Study completion Aug 31, 2025
Sponsor
- Lead sponsor
- BioXcel Therapeutics IncIndustry
- Sponsor type
- Industry
- First posted
- Apr 10, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open-label, multicenter, Phase 1b/2 study to identify the recommended Phase 2 dose and assess the efficacy and safety of talabostat administered orally, as monotherapy and in combination with pembrolizumab, in participants with mCRPC. Participants enrolled in the Phase 2a portion of the study will have either SCNC (Cohort A) or adenocarcinoma phenotype (Cohort B), while the Phase 2b randomized portion of the study will enroll only the histologic subtype(s) showing preliminary evidence in Phase 2a. The study will also assess other efficacy parameters, such as radiographic progression-free survival (rPFS), prostate-specific antigen progression-free survival (PSA PFS), overall survival (OS), and duration of response (DOR), as well as the safety of the combined treatment.
Conditions
- Prostate Cancer
- Neuroendocrine Tumors
- Small Cell Carcinoma
Interventions
TalabostatDrug
Oral Tablets
PembrolizumabDrug
Intravenous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 2a: Composite Response Rate (CRR)Time frame: Up to approximately 4 years and 4 months
- Phase 2b: Objective Response Rate (ORR)Time frame: Up to approximately 4 years and 4 months
Locations
12 sites in 2 countries. Site status is shown where the registry gives one.
University of California San Francisco (UCSF)
San Francisco, California
BioXcel Clinical Research Site
Denver, Colorado
Yale University
New Haven, Connecticut
Moffitt Cancer Center and Research Institute
Tampa, Florida
BioXcel Clinical Research Site
Detroit, Michigan
Center for Advanced Medicine / R.J. Zuckerberg Cancer Center (Northwell Health Cancer Institute)
Lake Success, New York
Weill Cornell Medicine New York
New York, New York
White Plains Hospital Center for Cancer Care
White Plains, New York
The Ohio State University
Columbus, Ohio
BioXcel Clinical Research Site
Glasgow, England, United Kingdom
BioXcel Clinical Research Site
London, Great Britain, United Kingdom
BioXcel Clinical Research Site
Sutton, Surrey, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.